United States

Profile: Neurobiological Technologies Inc (NTII.PK)

NTII.PK on OTC Markets Group

13 Aug 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company.

On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.

Company Address

Neurobiological Technologies Inc

2010 Crow Canyon Pl Ste 100
SAN RAMON   CA   94583-1344
P: +1925.3593247
F: +1302.6365454

Company Web Links